{
    "nctId": "NCT01697345",
    "briefTitle": "Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy",
    "officialTitle": "Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Total Female Sexual Function Index (FSFI) Score",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with breast cancer\n* Currently taking an aromatase inhibitor (AI)\n* Age \\> 50 years of age\n* Postmenopausal, or two years since last menstrual cycle\n* Urogenital/vulvovaginal symptoms such as vaginal dryness and pain with intercourse\n* Changes in sexual health quality of life/sexual functioning since starting AI therapy\n\nExclusion Criteria:\n\n* The use of other treatments for breast cancer such as chemotherapy or radiation within the past 12 months\n* A known sensitivity to medications containing testosterone\n* The use of exogenous hormone replacement therapy (HRT) in the past three months, including systemic and local estrogen or testosterone therapy",
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}